•  
  •  
 

Policies

Contents

Focus and Scope

For more information, please see Pharmacology and Clinical Pharmacy Research Focus and Scope page.

{ top }

Section Policies

Original Research

✓ Open Submissions

✓ Indexed

✓ Peer Reviewed

Article Review

✓ Open Submissions

✓ Indexed

✓ Peer Reviewed

Case Report

✓ Open Submissions

✓ Indexed

✓ Peer Reviewed

Brief Research Communications

✓ Open Submissions

✓ Indexed

✓ Peer Reviewed

{ top }

Peer Review Process

Articles that have been submitted will undergo an initial review by the editor and assistant editor to check whether the type of article, topic, and format meet the established requirements. The initial review will take 1-2 weeks. Articles that have undergone initial review and require revisions will be returned to the author to complete or revise the article within a week. Articles that have been submitted and passed the initial review will be checked for plagiarism and AI-generated content before being sent to reviewers.

Every article that has passed all stages of the initial review will be reviewed anonymously by two reviewers (blind peer review). Manuscripts submitted to reviewers do not contain any information related to the author or the author's affiliation. The review process will take 1-2 months, depending on the number of reviews required for each article.

The editor decision on articles, which can be “manuscripts accepted,” “major revision,” “minor revision,” and “manuscripts rejected,” is made by the editorial team based on the review results. Articles that require revision will be returned to the author and given 1-2 weeks to make revisions, depending on the extent of the revisions required. Articles that the author has revised will be re-evaluated, and a final decision will be made.

Accepted articles will undergo copyediting and proofreading to correct grammar and spelling errors, adjust tables and images according to journal standards, and edit the article layout according to the journal layout. Articles that are ready for publication will be scheduled after the PCPR Journal Team confirms payment for the article. Final approval from the author is also required before the article is published.

{ top }

Publication Frequency

Pharmacology and Clinical Pharmacy Research (PCPR) publish three issues per year, in April, August, and December.

{ top }

Open Access Policy

Pharmacology and Clinical Pharmacy Research (PCPR) is an open-access journal that makes articles freely available to the public to support the growth of knowledge. Access to full articles that have been published is free of charge to readers and institutions. This journal is indexed by DOAJ, Cross-Ref, Google Scholar, Index Copernicus, and Garuda-Ristekdikti., and all articles have a DOI. Articles are licensed under the Creative Commons Attribution License (CC-BY-NC). This is an open-access journal with abstracts and articles displayed in hypertext meta-language (HTML), and full articles available for download in Adobe Portable Document Format (PDF).

{ top }

Plagiarism Policy

Pharmacology and Clinical Pharmacy Research (PCPR) uphold academic integrity and scientific publication ethics. Therefore, every manuscript submitted to this journal must be the original work of the author and free from plagiarism.

Plagiarism includes, but is not limited to

  1. Copying part or all of another person's work without clearly citing the source;
  2. Claiming another person's ideas, data, or research results as one's own;
  3. Self-plagiarism, which is republishing one's own previously published work without adequate citation or permission;
  4. Inadequate paraphrasing so that the substance of the original work remains dominant.

Each submitted manuscript will be checked for similarity using plagiarism-detection software before entering the peer-review process.

If plagiarism is detected, the manuscript will be rejected and returned to the author. If plagiarism is found after the article is published, the journal will retract the article in accordance with publication guidelines and ethics.

Authors are fully responsible for the originality of the manuscripts they submit. They must ensure that all sources are properly cited and that the manuscripts have not been published and are not currently under consideration by other journals.

{ top }

Policy of Revenue Sources, Advertising, and Direct Marketing

Revenue Sources

Pharmacology and Clinical Pharmacy Research (PCPR) receives income from various sources to ensure the quality of the peer-review process and article publication is maintained. Sources of income consist of publication fees (APC) and support from the Faculty of Pharmacy, Universitas Padjadjaran. Sources of income do not influence the editorial team in making decisions.

Publication fees for Indonesian authors consist of a submission fee of IDR 250,000, paid upon submission, and a publication fee (APC) of IDR 2,000,000, paid after the article is accepted and scheduled for publication.

Publication fees for authors outside Indonesia consist solely of a publication fee (APC) of USD 200, payable after the article is accepted and scheduled for publication.

Advertising Policy

Pharmacology and Clinical Pharmacy Research (PCPR) does not accept advertisements from other parties.

Direct Marketing Policy

Pharmacology and Clinical Pharmacy Research (PCPR) conduct direct marketing activities in an ethical, transparent, and responsible manner. All promotional communications are accurate, appropriate, and limited to academic purposes, such as journal information and calls for papers. Personal data are used solely for scholarly communication and are not shared with third parties without consent. Direct marketing activities do not influence editorial decisions or the peer review process.

{ top }

Retraction, Withdrawal, and Correction Policy

Pharmacology and Clinical Pharmacy Research (PCPR) has adopted article retraction guidelines based on the COPE Retraction Guidelines.

Retraction

Articles that have been published and are found to violate the publication ethics code and research ethics code may be retracted. Notification of the article’s retraction will be sent to the author via email. Although the original publication has been retracted, it remains accessible to readers, and a retraction statement informing readers of the invalidity of the published work is hyperlinked to the original published document.

Articles may be retracted from Pharmacology and Clinical Pharmacy (PCPR) for several reasons, such as:

  1. The article or data within the article has been published in another journal without permission or justification.
  2. The article is suspected of plagiarism.
  3. The article is suspected of violating research ethics.

Withdrawal

Article withdrawal may occur before publication if serious issues are identified, such as duplicate submission, ethical concerns, or author request with valid justification. Withdrawn manuscripts will not be published or assigned to an issue. The withdrawal process is handled transparently and in accordance with editorial policies. Once withdrawn, the manuscript cannot be resubmitted to the journal without editorial approval.

Correction

Corrections are issued for articles containing minor errors that do not affect the overall results or conclusions. A correction notice will be published and linked to the original article. The correction clearly describes the changes made and the reason for the update. All corrections follow best practices recommended by COPE.

Erratum (Publisher Correction) refers to corrections made for errors introduced by the publisher during the production process. Such changes are normally communicated to the authors at the proof stage and, whenever possible, corrected before final publication. An erratum is issued for scientifically relevant issues, including significant formatting problems, missing or unclear figures, text omissions, or authorship inaccuracies such as the inclusion or omission of contributors who do not meet or do meet authorship criteria. Minor typographical or grammatical errors that do not affect the clarity or interpretation of the article do not warrant an erratum. Authors are responsible for carefully reviewing the final proofs to ensure accuracy.

Corrigendum (Author Correction) refers to a post-acceptance amendment requested by the authors. Authors must notify the journal editor, who will assess the significance of the proposed change and determine the appropriate action. A corrigendum for a published article will only be issued upon editorial approval and in accordance with the editor’s instructions.

Publisher’s notes are issued to inform readers that an article has been corrected after publication. These notes are published by the Publisher in cases where typographical or production errors attributable to the Publisher affect the accuracy of the article’s metadata (such as the title, author information, or byline) or substantially hinder comprehension of the content. In such cases, the original article may be replaced with a corrected version, and the publisher’s note will be made openly accessible. Minor errors that do not compromise metadata integrity, reader understanding, or scientific content may be corrected at the Publisher’s discretion.

{ top }

Complaint and Appeals

Pharmacology and Clinical Pharmacy Research (PCPR) deals with complaints and appeals in accordance with the recommendations of the Committee on Publication Ethics (COPE): https://publicationethics.org/appeals. in a fair, transparent, and timely manner.

Complaints and appeals may relate to the editorial process, peer review, publication ethics, or journal management. All complaints and appeals must be submitted in writing to the editorial team via email at pcpreditorialteam@gmail.com and will be reviewed objectively by the Editor-in-Chief or another editor appointed as representative. Complaints and appeals may take the form of

  1. Review of rejected manuscripts and appeals against rejection
  2. Complaints about scientific content
  3. Complaints about the process, such as the time required for the review process.
  4. Complaints about publication ethics, including any complaints and/or appeals related to publication ethics violations that have occurred, either from the author or reviewer.

All complaints, appeals, and requests for review will be addressed within a maximum of two weeks. The Editor-in-Chief will conduct an investigation in accordance with COPE guidelines. This investigation will determine whether the proper procedures were followed and assess whether the concerns were addressed fairly and without bias.

{ top }

Data Sharing Policy

If required, Pharmacology and Clinical Pharmacy Research (PCPR) encourage authors to share data to support publication and to link data to published articles. “Research data” refers to the results of observations or experiments that confirm research findings, including but not limited to raw data, processed data, software, algorithms, protocols, models, methods, and other related materials. By following this policy, authors who have made their research data accessible in a data repository can link their articles directly to the dataset.

{ top }

Allegation of Misconduct

The journal is committed to upholding the highest standards of publication ethics and follows the guidelines of the Committee on Publication Ethics (COPE) in addressing allegations of research or publication misconduct. Research misconduct means fabrication, falsification, citation manipulation or plagiarism in producing, performing, or reviewing research, writing an article by authors, or reporting research results. When authors are found to have been involved with research misconduct or other serious irregularities involving articles that have been published in scientific journals, Editors have a responsibility to ensure the accuracy and integrity of the scientific record.

If an allegation is found to have merit, the journal will conduct an investigation in accordance with COPE procedures, which may involve consultation with authors, reviewers, editorial board members, or relevant institutions. Appropriate actions will be taken based on the findings, including correction, retraction, or rejection of the manuscript, while ensuring fairness, transparency, and due process.

The first step involves determining the validity of the allegations and assessing whether they meet the definition of research misconduct. This initial step also involves determining whether the individual making the allegations of misconduct has a relevant conflict of interest.

If there is a possibility of scientific misconduct or other substantial research irregularities, the allegations will be communicated to the author concerned, who, on behalf of all co-authors, will be asked to provide a detailed response. Once the response has been received and evaluated, additional review and expert involvement (e.g., statistical reviewers) may be undertaken. In cases where the likelihood of ethical misconduct is very low, clarification, additional analysis, or both, published as a letter to the editor, and often including a correction notice and correction to the published article, may be sufficient.

Institutions are expected to conduct thorough and appropriate investigations into allegations of scientific misconduct. Ultimately, authors, journals, and institutions have an important responsibility to ensure the accuracy of scientific records. By appropriately responding to concerns about scientific ethical violations and taking necessary actions based on their evaluation, such as corrections, retractions, and retractions, the Pharmacology and Clinical Pharmacy Journal (PCPR) will continue to fulfill its responsibility to ensure the validity and integrity of scientific records.

{ top }

Informed Consent, Ethical Clearance, and Animal Ethics Policy

Informed Consent

All research involving human participants must be conducted in accordance with internationally recognized ethical standards. Authors are required to obtain prior written informed consent from all participants or their legally authorized representatives and to explicitly state this in the manuscript. Measures to protect participants’ privacy, confidentiality, and personal data must be clearly described, and identifying information should not be disclosed unless essential and explicitly consented to.

Ethical Clearance

Studies involving human subjects must receive ethical approval from a recognized ethics committee or institutional review board before the research is conducted. The manuscript must include the name of the approving body and the ethical approval or reference number, where applicable. The journal reserves the right to request supporting documentation and may reject or retract articles that do not meet ethical approval requirements.

Animal Ethics

Research involving animals must comply with internationally accepted guidelines for the care and use of laboratory animals. Authors must confirm that all procedures were reviewed and approved by an appropriate animal ethics committee and conducted in accordance with relevant institutional, national, or international regulations. The journal requires that animal studies minimize pain, suffering, and distress, and reserves the right to reject manuscripts that do not meet acceptable ethical standards.

{ top }

Authorship and Contributorship

Pharmacology and Clinical Pharmacy Research (PCPR) adopt internationally accepted standards of authorship and follows ethical guidelines to ensure transparency and accountability in scholarly publishing.

Authorship Criteria

Authorship should be limited to individuals who have made substantial intellectual contributions to the work. Each listed author must have significantly contributed to the conception or design of the study, data acquisition, analysis, or interpretation, participated in drafting or critically revising the manuscript, and approved the final version for publication. All authors must agree to be accountable for the accuracy and integrity of the work. Authors for original research are not permitted to be sole authors.

Contributors who do not meet the criteria for authorship should not be listed as authors, but they should be acknowledged. These individuals can be listed in the Acknowledgements section along with a description of their contribution to the research.

Submission of a manuscript to Pharmacology and Clinical Pharmacy (PCPR) means that all listed authors have approved all content, including the list of authors and the authorship statement.

Author Responsibility

Authors of each manuscript are required to confirm that:

  1. The manuscript has not been published or submitted to another journal.
  2. The authors have made significant contributions to the work and approve the final version of the manuscript.
  3. Their work complies with ethical standards;
  4. They are responsible for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are investigated and resolved appropriately;
  5. They have obtained all necessary permissions to publish images or tables in the manuscript and ensure that the authors will pay the Article Processing Charge (APC) if applicable.

Contributorship

Individuals who contributed to the research but do not meet the criteria for authorship should be acknowledged appropriately as contributors. Their specific roles (such as technical assistance, data collection, language editing, or funding acquisition) should be clearly described in the acknowledgments or contributorship statement. Contributors do not bear the same responsibility as authors for the overall content of the article.

Changes to Authorship

Any addition, removal, or rearrangement of authors’ names after submission must be approved by all authors and justified in writing to the Editor-in-Chief. The journal reserves the right to request supporting documentation and to reject changes that do not comply with ethical standards or publication policies.

{ top }

Generative AI Policy

Pharmacology and Clinical Pharmacy Research (PCPR) recognize the responsible use of generative artificial intelligence (AI) tools in scholarly research and publishing. The use of such tools must be transparent, ethical, and must not compromise the integrity, originality, or accountability of the research.

Permissible Use

Generative AI tools may be used solely to assist with language editing, grammar correction, or readability improvement. Such use does not require detailed methodological description but remains under the full responsibility of the authors. The use of basic tools such as grammar and spelling checkers (e.g., Grammarly), reference management software (e.g., EndNote, Zotero), or standard text editors and word processors (e.g., Microsoft Word, Google Docs) does not need to be disclosed in generative AI tools in manuscripts.

Disclosure Requirements

Authors must disclose the use of generative AI if the tool contributed to content generation, data analysis, interpretation, image creation, or any aspect that may influence the scientific content of the manuscript. Disclosure must include the name of the tool, its version (if applicable), and the purpose of use, and should be stated in the Methods section or in a dedicated AI disclosure statement.

Disclosure example:

Statement: During the preparation of this work, the author used [NAME OF TOOL/SERVICE] for [REASON]. After using this tool/service, the author reviewed and edited the content as necessary and takes full responsibility for the content of the publication.

Methodological Transparency

When generative AI is used as part of the research process, authors must clearly describe how the tool was applied, the inputs provided, how outputs were verified, and how potential bias or limitations were addressed. This description must be sufficiently detailed to allow evaluation of the validity and reproducibility of the study.

Prohibited Use

Generative AI tools must not be listed as authors or co-authors and cannot assume responsibility for the work. AI must not be used to fabricate or falsify data, manipulate images, generate misleading or false references, or replace critical scientific judgment. Failure to disclose or inappropriate use of AI may result in rejection, correction, or retraction.

Author Accountability

Authors remain fully accountable for the originality, accuracy, and integrity of all content in the manuscript, including any content produced or assisted by AI tools. PCPR reserves the right to request additional information regarding AI use and to take action in accordance with COPE and ICMJE ethical standards.

Use by Reviewers and Editors

Reviewers and editors should not use publicly available AI tools to summarize, review, or evaluate manuscripts to maintain confidentiality. Secure institutional AI tools may be used for editorial management, plagiarism detection, or language checking with strict privacy standards.

Editorial Actions

Manuscripts with undisclosed or unethical use of AI may be rejected or retracted in accordance with publication ethics guidelines.

Policy Updates

This policy will be reviewed and updated periodically in line with developments in AI technology and international publication standards. This policy was developed in accordance with COPE, ICMJE, and WAME recommendations on the responsible use of Generative AI in scientific publishing (2023–2024).

{ top }